Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 1/20 | 0.53 |
| ▸ | GRK6 | P43250 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 6/20 | 0.44 |
| ▸ | CA2 | P00918 | 6/20 | 0.44 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.44 |
| ▸ | HK1 | P19367 | 1/20 | 0.44 |
| ▸ | HK2 | P52789 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4901149 | 0.84 | ADK (0.56) | ADKGRK6TSHRCA1CA2 | |
| SCHEMBL9399690 | 0.80 | CA1 (0.64) | ADKGRK6TSHRCA1CA2 | |
| SCHEMBL14478587 | 0.80 | CA1 (0.64) | ADKGRK6TSHRCA1CA2 | |
| SCHEMBL14353232 | 0.80 | CA1 (0.64) | ADKGRK6TSHRCA1CA2 | |
| SCHEMBL17612649 | 0.78 | GRK6 (0.50) | GRK6GAATSHRCA1CA2 | |
| SCHEMBL4875694 | 0.78 | GRK6 (0.59) | ADKGRK6TSHRCA1CA2 | |
| SCHEMBL16941671 | 0.76 | TSHR (0.44) | ADKGRK6TSHRCA1CA2 | |
| SCHEMBL16946211 | 0.76 | TSHR (0.44) | ADKGRK6TSHRCA1CA2 | |
| SCHEMBL15436010 | 0.76 | TSHR (0.44) | ADKGRK6TSHRCA1CA2 | |
| SCHEMBL15445169 | 0.76 | TSHR (0.44) | ADKGRK6TSHRCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090774-A1 | Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations | PTC THERAPEUTICS, INC. | 2008-04-17 | — | — | US | claimed |
| US-20040067900-A1 | Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations | PTC THERAPEUTICS, INC. | 2004-04-08 | — | — | US | claimed |
| US-20160199357-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCIATED THEREWITH | PTC THERAPEUTICS, INC. | 2016-07-14 | — | — | US | disclosed |
| US-9289398-B2 | Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith | PTC THERAPEUTICS, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20110046136-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCICATED THEREWITH | THERAPEUTICS, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-7449570-B2 | Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases | PTC THERAPEUTICS, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-7449570-B2 | Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases | PTC THERAPEUTICS, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-20080090774-A1 | Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations | PTC THERAPEUTICS, INC. | 2008-04-17 | — | — | US | disclosed |
| US-20080090774-A1 | Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations | PTC THERAPEUTICS, INC. | 2008-04-17 | — | — | US | disclosed |
| US-7291603-B2 | Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations | PTC THERAPEUTICS, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291603-B2 | Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations | PTC THERAPEUTICS, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-20060166926-A1 | Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases | PTC THERAPEUTICS, INC. | 2006-07-27 | — | — | US | disclosed |
| US-20040067900-A1 | Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations | PTC THERAPEUTICS, INC. | 2004-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046136-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCICATED THEREWITH | UPF1, DNAJC10, RNGTT | ADK 3337/4885GRK6 4133/4885CYP1A2 4786/4885 |
| US-20160199357-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCIATED THEREWITH | UPF1, DNAJC10, RNGTT | ADK 3595/4885GRK6 4181/4885CYP1A2 4778/4885 |
| US-20060166926-A1 | Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases | NSUN2, UPF1, NSUN3 | ADK 523/4885GRK6 3946/4885CYP1A2 4783/4885 |
| US-20040067900-A1 | Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations | NSUN2, RNMT, NSUN3 | ADK 198/4885GRK6 3642/4885CYP1A2 4717/4885 |
| US-20080090774-A1 | Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations | NSUN2, RNMT, NSUN3 | ADK 198/4885GRK6 3642/4885CYP1A2 4717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.